Phase 1 open-label, dose escalation study of INB03 in patients with metastatic cancer with increased inflammatory biomarkers in peripheral blood
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
At a glance
- Drugs INB 03 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Renal cancer
- Focus Adverse reactions; Biomarker; First in man; Pharmacokinetics; Therapeutic Use
- 01 Aug 2018 Anticipated date last participant enrolled is 1/4/2019
- 01 Aug 2018 Planned End Date changed from 17 May 2019 to 4 Oct 2019.
- 01 Aug 2018 Planned initiation date (Estimated date of first participant enrollment) changed from 4 Jun 2018 to 6 Aug 2018.